CENTRAL AUTONOMIC PHARMACOLOGY OF THYROTROPIN
RELEASING HORMONE

Anna-Leena Sirén and Giora Feuerstein

Neurobiology Research Division, Department of Neurology
Uniformed Services University of the Health Sciences
4301 Jones Bridge Road, Bethesda, MD 20814-4799

Introduction

Thyrotropin releasing hormone (TRH, 1-pyroglutamyl-1-histidyl-1-prolinamide) was the first hypothalamic releasing substance to be isolated, chemically characterized and synthetized /1/. The studies to date have revealed that the thyrotropin release from the pituitary gland is only one of the numerous actions of TRH. In addition to its endocrine actions (TSH and prolactin release) this tripeptide has central nervous system actions totally unrelated to its effects on the hypothalamo-pituitary axis. This review aims to summarize the studies on the central nervous system actions of TRH with special emphasis on the autonomic pharmacology of this peptide.

TRH and its Receptors in the Central Nervous System

TRH-like immunoreactivity is widely distributed throughout the whole nervous system of vertebrates including man, guinea pig, rat, mouse and frog. TRH is also present in plants and in lower animals which totally lack the thyroid functions. Moreover, over 70% of the total central nervous system TRH is located outside the hypothalamus, although the highest local concentrations of TRH in the brain are found in the hypothalamus and pituitary gland. Outside the nervous system, relatively high levels of TRH are found in the gastrointestinal system (for review 1,2).

Both hypothalamic and extrahypothalamic brain synaptosomes contain high amounts of TRH immunoreactivity. Furthermore, TRH has been shown to be present in nerve endings. In brain synaptosomes, fragments and slices, in vitro TRH is both released and taken up /1,2/. Furthermore, TRH was shown to be colocalized with neurotransmitters such as 5-hydroxytryptamine (5-HT) and substance P in the rat brain /3/. More recent studies indicate that TRH arises from the post-translational cleavage of a large precursor protein of 123 amino acids /4/. In the rat brain both TRH and pro-TRH have been found in...
neuronal perikarya of the parvocellular division of the paraventricular nucleus of the hypothalamus and the raphe complex of the medulla /5/. The distribution of TRH receptors is limited to relatively few tissues such as brain, pituitary, retina and spinal cord /1/. Burt and Snyder /6/ were the first to demonstrate the stereospecific binding of $^3$HTRH to rat brain and to establish high and low affinity binding sites. Recently, TRH-receptors have been shown to be present also in human brain and spinal cord /7,8/. Autoradiographic studies in the rat brain have revealed that high levels of TRH receptors are found in the rhinencephalon, including accessory olfactory bulb, nuclei of amygdala and hippocampus; moderate to low levels were found in thalamus and hypothalamus and in most regions of the rhombencephalon /9-12/. Although comparisons of the distribution of TRH receptors to TRH immunoreactivity indicates that in most brain areas there is little obvious correlation between levels of TRH peptide and its receptors, the extensive distribution of TRH receptors in the CNS provides an explanation for the variety of behavioral and autonomic effects observed when TRH is administered into the brain.

Behavioral and Neurological Effects

In experimental animals TRH has an an analeptic effect and antagonizes narcosis induced by a variety of CNS depressant agents such as ethanol, barbiturates and ketamine. Other typical effects of TRH are forepaw tremor, “wet dog shakes,” alert appearance and overall arousal /13-15/.

In some studies TRH has been shown to have amphetamine-like actions (reduction in operant tasks and eating behavior). Increased locomotor activity by centrally administered TRH was first shown by Plotnikoff /16/. This effect is antagonized by haloperidol or pimozide /17/, suggesting that dopamine receptors in mesolimbic system mediate this effect of TRH. However, TRH has not been shown to have any effect on dopamine or amphetamine induced circling behaviour in unilaterally nigrostriatal lesioned rats /18/. In microiontophoretic studies TRH has been reported to enhance the effects of acetylcholine on cortical neurons /19/.

The analeptic effect and arousal induced by TRH in experimental animals led to the hypothesis that this peptide might have some beneficial effects in human depression. In the early seventies, intravenously injected TRH was shown to have “antidepressant” effects in human depression /20,21/. In experimental animals antidepressant drugs have been shown to cause increased release of TRH in brain tissue ex vivo /22/. The therapeutic activity of antidepressant drugs, on the other hand, has been related to their effect on
5-HT neurotransmission /23/. Since TRH is colocalized with 5-HT in the brain and reported to have some beneficial effect on depression in man, it might act as a comodulator of 5-HT which causes adaptive changes in 5-HT neurotransmission. However, clinical investigations with TRH have attempted to establish its use in depression but in no case have the results proved decisive /13,24/. Other mental disorders where TRH has been tried clinically include schizophrenia and alcohol withdrawal /13,24/.

TRH increases skeletal muscle tonus in experimental animals probably by a direct action on spinal motor neurons /19,25/. In the rat spinal cord motoneurons TRH has been shown to coexist with 5-HT and substance P /1,3/ and in lumbar spinal motoneurons of urethane-anesthetized rats 5-HT, substance P and TRH were recently shown to enhance both glutamate and aspartate-induced excitation of the motoneurons /26/.

Intravenously injected TRH has been proven to be of benefit in reducing weakness and spasticity in motoneurone disease and in promoting recovery in both motoneurone disease and spinal trauma /27-29/. These effects were postulated to be mediated primarily by stimulation of TRH receptors in spinal cord, but spinal hypertension and increased blood flow after spinal injury were also suggested to contribute to the therapeutic effect of TRH. Other neurological disorders where TRH has been tried as treatment include Parkinson’s disease and childhood hyperactivity with varying improvement in these clinical conditions /24/.

Thermoregulation

Central nervous system administration of TRH or its stable analogs antagonizes reserpine-induced hypothermia. In intact animals, depending on the species, ambient temperature and the route of administration, TRH might produce hypothermia or hyperthermia. One of the main metabolites of TRH in the body, histidyl-proline-diketopiperazine, has been reported to antagonize the TRH-induced hyperthermia in the rat /30/. For a more detailed review over the issue see Horita et al. /14/ and Metcalf /13/.

Gastrointestinal Effects

TRH increases colonic and duodenic activity and gastric acid secretion by a central nervous system activation of parasympathetic outflow. In vitro TRH has been shown to stimulate the guinea pig ileum and rat antrum, pyloric sphincter and colon but the significance of these effects is not clear. Since moderate levels of TRH immunoreactivity are found in the gastrointestinal
system, this peptide might have a physiological role in regulation of gastric
and intestinal motility. For further details see recent reviews by Horita et al.
/14/, Morley /24/ and Prasad /1/.

Respiratory Effects

Central nervous system administration of TRH produces increases in
ventilatory rate /31,32/ and respiratory minute volume with no change in
tidal volume /31/. In halothane anesthetized rats, depletion of serotonin with
pargyline and 5,7-dihydroxy-tryptamine attenuated the tachypnea induced
by TRH intracerebroventricularly (icv) as well as neonatal treatment with
capsaicin or acute vagotomy in adult rats /33/. Moreover, the supersensitivity
of serotonin depleted rats to TRH was shown to be a result of an elevated
PCO₂, thus suggesting that the respiratory responses to exogenous TRH can
depend partly on afferent vagal input, but that other endogenous inputs to
the respiratory center such as CO₂ also contribute to the magnitude of the
observed response by non-vagal routes. TRH immunoreactivity has been
found in respiratory division of nucleus tractus solitarius (NTS) /34/. It was
recently reported /35/ that in a pig brainstem preparation in vitro TRH
induced rhythmic bursting of neurons in the respiratory division of NTS. On
the other hand, it was shown recently that intravenous injection of TRH
inhibited the leukotriene D₄-induced bronchoconstriction in the guinea pig
/36/. This might have some contribution to the beneficial effect of TRH in
anaphylactic shock (see below).

Cardiovascular Effects

TRH has a well documented pressor effect in both experimental animals
/32,37-40/ and in man /41-44/. In animals the TRH-induced increment in
blood pressure is accompanied by a tachycardia, while in humans the heart
rate does not significantly change after TRH-administrations. These cardio-
vascular actions of TRH are likely to be mediated via central nervous system
since more than a thousand fold higher doses are needed to induce
cardiovascular changes after systemic administrations /28/ than after injections
into the brain ventricles or distinct brain nuclei /40,45,46/. Moreover,
transections in the cervical spinal cord abolished the pressor response to icv
injected TRH in the rabbit, while spinal transections below T₁ had no
influence on TRH-induced hypertensive action /38/. The pressor effect of
TRH in leukotriene D₄-induced hypotension is also totally abolished in the
pithed rat in which the total central nervous system has been destroyed /47/.
The site of the cardiovascular actions of TRH in the brain is not known. Feuerstein and co-workers /40/ injected subnanomolar doses of TRH into the nucelus preopticus medialis (POM) of hypothalamus in the conscious rat and found increases in both blood pressure and heart rate. Microinjections of picomolar amounts of TRH into different hypothalamic regions of halothane anesthetized rats were also shown to elicit moderate changes in mean arterial pressure and heart rate with no changes in respiratory rate or body temperature /45/. However, the doses of TRH used in these studies are high enough to elicit increments of blood pressure and heart rate also after icv administration /32,46/. A recent report by Paakkari et al. /48/ suggests that the pressor effect of TRH arises from the region of the fourth ventricle whereas the cardio-accelerator effect is likely to be mediated by activation of some forebrain structures. This suggestion is contradicted by the earlier findings /40/ that TRH, microinjected into the NTS, produced a brief depressor effect on blood pressure and a delayed increase in heart rate.

Although the pressor and tachycardic effects of TRH have been well characterized, little is known about the hemodynamic changes mediating these gross cardiovascular changes. In anesthetized rabbits a systemic injection of TRH has been shown to increase cerebral blood flow /49/. By using the directional ultrasound Doppler technique we recently reported a differential regional blood flow pattern after both subnanomolar doses of TRH icv as well as by a high systemic dose /46/: The blood flow to skeletal muscles significantly increased while the renal (and to a lesser degree the mesenteric) blood flow dose-dependently decreased after TRH injections. The pattern of these blood flow changes resembled those induced by intravenous injection of epinephrine, suggesting that these effects might be mediated by the activation of the sympatho-adrenomedullary axis. We have also shown that in the conscious rat the increase in blood pressure by TRH is likely to be due to an increase in cardiac output, while due to the differential blood flow changes the total peripheral resistance remains unchanged in intact rats /46/.

Concomitantly with the increments in blood pressure and heart rate, TRH induces increase in plasma catecholamines in both animals /40,50/ and man /42/. These findings led to the suggestion that the cardiovascular effects of TRH are mediated by an activation of sympathetic outflow. The pressor effect of TRH icv in rat endotoxic shock has been shown to be abolished by adrenal demedullectomy /51/. In conscious intact rats the tachycardic effect of TRH injected into the POM was also blocked and the pressor response somewhat reduced in bretylium treated adrenal demedullated rats /40/. Studies in progress in our laboratory have shown that the renal vasoconstrictor response to icv or iv administered TRH is reduced to about 50% in adrenal
demedullated rats while the increase in skeletal muscle blood flow is blocked only after bretylium treatment, suggesting that both the catecholamine release from adrenal medulla and the activation of sympathetic nerves contribute to these actions of TRH. However, some non-adrenergic mechanisms are also likely to be involved in the cardiovascular actions of TRH, since its effects on blood pressure and heart rate were not affected by pretreatments with ganglion blockers, reserpine, phentolamine or propranolol /52,38, and unpublished results of our laboratory/. This suggestion is further supported by the recent clinical findings that the rise in blood pressure by intravenous TRH in humans is not accompanied with any changes in plasma catecholamines /44/. Since measuring plasma catecholamines only might not be a good index of sympathetic tone, these findings do not exclude the role of sympathetic activation in the effects of TRH.

In addition to the sympathetic nervous system other pressor systems have been related to the cardiovascular effects of TRH. Central nervous system administration of TRH caused increments in plasma levels of vasopressin in rabbits /52,53/ but had no effect on plasma vasopressin in dogs /54/. We found only slight and biologically insignificant increases in plasma vasopressin after system administration of TRH in conscious rats. Moreover, Horita et al. /52/ have shown that the TRH-induced increase in vasopressin can be differentiated from its hypertensive effect; hexamethonium blocked the increment of plasma vasopressin but not the pressor response to icv administered TRH in anesthetized rabbits. It was recently found that the pressor effect of TRH icv in urethane-anesthetized rats is not blocked by a vasopressin antagonist /55/.

Another pressor system which has been related to the cardiovascular actions of TRH is the renin-angiotensin system. The pressor effect of icv administered TRH was attenuated by treatment with the angiotensin converting enzyme inhibitor captopril or with the angiotensin receptor antagonist /55/. However, the endogenous renin-angiotensin system plays hardly any role in the effects of TRH, since administrations of this peptide to either humans /42/ or rats (unpublished observation of our laboratory) had no effect on plasma renin activity.

TRH in Shock and Trauma

Since TRH has been shown to be a potent cardiotonic and respiratory stimulator it was only natural to assume that such a compound might have therapeutic potential in cardiovascular states in which respiratory, cardiac or hemodynamic variables are severely depressed. This suggestion was further
supported by experiments showing that TRH effectively blocks opiates and opioid peptides mediated effects /56/; since activation of the endogenous opioid system has been argued to play an important role in cardiovascular depression following various shock stimuli /56/, antagonism of opioid mediated cardiovascular depression by TRH was considered an additional mechanism for the potential beneficial actions of TRH in shock states /56/.

The potential therapeutic capacity of TRH was examined in several shock and trauma situations: hemorrhage, endotoxemia, anaphylaxis, spinal cord injury and multiple organ trauma.

In hemorrhagic shock, original studies by Holaday et al. /57/ demonstrated that TRH can reverse the systemic hypotension produced by bleeding. The pressor response to TRH in hypovolemic hypotension was confirmed in other studies /58,59,60/. In a study conducted on anesthetized, cynomolgus monkeys, TRH was shown to increase myocardial contractility after hemorrhage /59/. Moreover, in the anesthetized rat exposed to severe bleeding TRH was shown to increase cardiac output along with mean arterial pressure /60/. However, in none of the studies cited above did TRH improve the survival rate of various experimental animals exposed to hemorrhagic shock; in a more recent study it was shown that TRH decreased the survival rate of conscious rats exposed to hypovolemic hypotension, a phenomenon most probably related to the substantial reduction in essential organ blood flow due to increase in vascular resistance /60/. Thus, the beneficial effect of TRH in hemorrhagic shock or other forms of hypovolemic hypotension is doubtful and extreme caution should be exercised in extrapolating the early reports on pressor effects of TRH in hemorrhage to therapeutic efficacy in both experimental animals and humans.

A totally different form of shock is lipopolysaccharide (LPS) endotoxemia. In this form of shock the intracellular volume is primarily preserved yet cardiac depression, pulmonary hypertension and organ blood flow are severely deranged. In LPS endotoxemia, TRH was shown to produce a pressor response /57,61,62/. However, in this form of shock, short term survival (2 hours) was found to be improved by TRH treatment but this effect was not dose dependent. In a study conducted on cynomolgus monkeys, TRH treatment failed to improve survival in severe endotoxemia in spite of a substantial pressor effect /62/. Further experiments are necessary to determine whether or not TRH might have a role in treatment of endotoxic shock.

Anaphylactic shock is still another form of shock which is mediated by specific immune response cells and mediators such as leukotrienes, histamine, PAFacether and others (for review see 63). The anaphylactic shock is
characterized by severe hemodynamic derangements which include cardiac depression, hypotension and shock. TRH has been shown to reverse anaphylactic shock in the mouse /64,65/ or guinea pigs /66/; in the mouse, TRH substantially improved the survival rate in anaphylactic shock /64/. The beneficial effect of TRH in this form of shock was attributed to central activation of the sympatho-adrenomedullary system, primarily through β1-adrenergic receptors /64,65/. Furthermore, the therapeutic effect of TRH in anaphylactic shock might also be the result of improved pulmonary functions due to alleviation of the bronchoconstriction /36/. TRH was also shown to reverse the shock syndrome produced by the specific shock-promoting mediators of anaphylaxis such as leukotrienes /67-69,47/ or platelet activating factor, PAF-acether /70/. In both shock paradigms, which were conducted on conscious rats or guinea pigs, the effect of TRH on survival rate was not examined. Thus, more definitive experimental work is necessary to determine whether TRH has significant therapeutic potential in immune reaction mediated shock states.

TRH was also utilized for therapeutic trials in several traumatic injury models. In multiple trauma models of the rat, TRH was found to exacerbate the shock state and decrease survival rate /58/. However, in a more discrete model of trauma, cervical spinal cord injury, TRH was found to improve long term neurologic recovery /28,29/. However, additional experimental work would be necessary to substantiate this report, especially in more clinically applicable models. It should be pointed out that although TRH was found to reduce blood flow in essential organs of oligemic rats /60/, it was also shown that systemic administration of TRH to anesthetized rabbits increases blood flow to many brain regions /49/. Thus, it might be possible that critical levels of blood flow to injured CNS zones might be preserved. This suggestion is contradicted, however, by the findings that TRH had no beneficial effect on ischemia induced by air embolization in experimental stroke in dogs /71/.

In summary, although preliminary experimental work raised hopes and expectations for therapeutic usage of TRH in a variety of states of shock and trauma, the present situation is clearly controversial.

Acknowledgements

This work was supported in part by USUHS Protocols No. RO9211 and RO9232. The opinions or assertions contained herein are the private ones of the authors and are not to be construed as official or reflecting the view of the Department of Defense or the Uniformed Services University of the Health Sciences. The authors wish to thank Ms. Wanda Patterson for her help in the preparation of this manuscript.
REFERENCES

17. Miyamoto M, Nagawa Y. Mesolimbic involvement in the locomotor stimulant


hormone (TRH)-containing nerve terminals in certain brain stem nuclei and in the spinal cord. Neurosci Lett 1975; 1: 133-139.


52. Horita A, Carina MA, Weltzman RE. Role of catecholamine and vasopressin release in the TRH-induced vasopressin response. Int: Usdin E, Kopiln JJ, Barchas J, eds,


70. Feuerstein G, Lux WE Jr, Ezra D, Hayes EC, Snyder F, Faden AI. Thyrotropin